Biosceptre Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $11.3M

  • Investors
  • 3

Biosceptre General Information

Description

Developer of targeted cancer immunotherapies designed to treat a broad range of malignancies. The company offers CAR-T cell therapies, antibody-based therapeutics, cancer vaccines, and its proprietary BRiDGECAR™ platform incorporating nfP2X7-targeted technology, enabling patients to receive targeted immuno-oncology treatments for solid and liquid tumors.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Babraham Main Hall
  • Babraham Research Campus, Babraham
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223
Primary Industry
Drug Discovery
Corporate Office
  • Babraham Main Hall
  • Babraham Research Campus, Babraham
  • Cambridge CB22 3AT
  • England, United Kingdom
+44 01223

Biosceptre Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biosceptre Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 27-Jul-2026 $11.3M Completed Generating Revenue
10. Secondary Transaction - Private 01-Apr-2026 Completed Generating Revenue
9. Later Stage VC (Series A) 05-Feb-2024 Completed Generating Revenue
8. Later Stage VC (Series A) 01-Nov-2023 Cancelled Generating Revenue
7. Later Stage VC (Series 3) 06-May-2021 Completed Generating Revenue
6. Later Stage VC (Series A) 21-Dec-2017 Completed Pre-Clinical Trials
5. Later Stage VC 06-Jun-2017 Completed Pre-Clinical Trials
4. Grant 01-Mar-2016 Completed Pre-Clinical Trials
3. Later Stage VC 01-Oct-2015 $7.3M $12M Completed Pre-Clinical Trials
2. Angel (individual) 09-Jul-2014 $4.7M $4.7M Completed Pre-Clinical Trials
To view Biosceptre’s complete valuation and funding history, request access »

Biosceptre Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary
Ordinary 2,000,000 $0.001339 $1.67 $1.67 1x $1.67 4.5%
Ordinary 30,000 $0.001339 $0.7 $0.7 1x $0.7 0.07%
To view Biosceptre’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Biosceptre Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of targeted cancer immunotherapies designed to treat a broad range of malignancies. The company offers CAR-T c
Drug Discovery
Cambridge, United Kingdom
15 As of 2026

Cambridge, MA
 

Rockville, MD
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Biosceptre Competitors (98)

One of Biosceptre’s 98 competitors is Agios Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agios Pharmaceuticals Formerly VC-backed Cambridge, MA
Macrogenics Formerly VC-backed Rockville, MD
Circle Pharma Venture Capital-Backed South San Francisco, CA
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
Light Chain Bioscience Formerly PE-Backed Geneva, Switzerland
You’re viewing 5 of 98 competitors. Get the full list »

Biosceptre Patents

Biosceptre Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4735479-A1 Molecules and methods for activating car t cells Pending 30-Jun-2023
WO-2025000037-A1 Molecules and methods for activating car t cells Inactive 30-Jun-2023
EP-4676521-A1 Chimeric antigen receptors for binding to dysfunctional p2x7 receptor Pending 08-Mar-2023
WO-2024182858-A1 Chimeric antigen receptors for binding to dysfunctional p2x7 receptor Inactive 08-Mar-2023
EP-4587465-A1 Enrichment of engineered immune cells Pending 14-Sep-2022 G01N33/532
To view Biosceptre’s complete patent history, request access »

Biosceptre Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Biosceptre Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Jungle Capital Venture Capital Minority
McKenny-McFarlane Capital PE/Buyout Minority
Norcliffe Capital Venture Capital Minority
To view Biosceptre’s complete investors history, request access »

Biosceptre FAQs

  • When was Biosceptre founded?

    Biosceptre was founded in 2004.

  • Where is Biosceptre headquartered?

    Biosceptre is headquartered in Cambridge, United Kingdom.

  • What is the size of Biosceptre?

    Biosceptre has 15 total employees.

  • What industry is Biosceptre in?

    Biosceptre’s primary industry is Drug Discovery.

  • Is Biosceptre a private or public company?

    Biosceptre is a Private company.

  • What is Biosceptre’s current revenue?

    The current revenue for Biosceptre is .

  • How much funding has Biosceptre raised over time?

    Biosceptre has raised $53.1M.

  • Who are Biosceptre’s investors?

    Jungle Capital, McKenny-McFarlane Capital, and Norcliffe Capital have invested in Biosceptre.

  • Who are Biosceptre’s competitors?

    Agios Pharmaceuticals, Macrogenics, Circle Pharma, CytomX Therapeutics, and Light Chain Bioscience are some of the 98 competitors of Biosceptre.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process